Evidence map›Paper›PMID 31812686›Full record

Trial reportThe journal of sexual medicine2020

Convergent-Divergent Validity and Correlates of the Day-to-Day Impact of Vaginal Aging Domain Scales in the MsFLASH Vaginal Health Trial.

Mary M Hunter, Katherine A Guthrie, Joseph C Larson, Susan D Reed, Caroline M Mitchell, Susan J Diem, Andrea Z LaCroix, Alison J Huang

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The journal of sexual medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07250490 (Validation of the DIVAS-Q), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07250490 completednot on this mapstarted 2022, after this paper: background citation

Validation of the DIVAS-Q (Day to Day Impact of Vulvovaginal Atrophic Symptoms Questionnaire) A Portuguese Patient-Reported Outcome Measure

TypeobservationalSponsorInstituto Politécnico de LeiriaRan2022 to 2025Enrolled300ConditionsVulvovaginal Atrophy, Genital Disorder, PROMs
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Observational
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Mary M HunterSchool of Nursing, University of California San Francisco, San Francisco, CA. Electronic address: mary.hunter@ucsf.edu.
Katherine A GuthrieFred Hutchinson Cancer Research Center, Seattle, WA.
Joseph C LarsonFred Hutchinson Cancer Research Center, Seattle, WA.
Susan D ReedObstetrics and Gynecology, University of Washington, Seattle, WA.
Caroline M MitchellObstetrics and Gynecology, Massachusetts General Hospital, Boston, MA.
Susan J DiemDepartment of Medicine, University of Minnesota, Minneapolis, MN.
Andrea Z LaCroixFamily Medicine and Public Health, University of California San Diego, La Jolla, CA.
Alison J HuangSchool of Medicine, University of California San Francisco, San Francisco, CA.
Fred Hutch Cancer Center · USCity College of San Francisco · USLa Jolla Alcohol Research · USMassachusetts General Hospital · USMinnesota Gastroenterology · USSan Francisco University High School · USUniversity of Washington · US

Funding

MsFLASH: Living a Healthy MenopauseR01AG048209 · NIA · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GUTHRIE, KATHERINE ADAMS, LACROIX, ANDREA Z. · 2015 to 2019
$7.2M
NIA NIH HHS R01 AG048209
6 · The paper itself

Abstract

introductionClinical research and management of postmenopausal vaginal symptoms have been limited by the lack of validated measures for assessing symptom impact.

aimTo evaluate convergent-divergent validity of the Day-to-Day Impact of Vaginal Aging (DIVA) questionnaire among postmenopausal women with moderate-to-severe vulvovaginal symptoms and identify demographic and clinical factors associated with greater symptom impact.

methodsWe examined baseline data from postmenopausal women with moderate-to-severe vulvovaginal itching, pain, irritation, dryness, or pain with intercourse in a randomized trial of vaginal estradiol, moisturizer, or placebo. In addition to completing the DIVA questionnaire, participants rated the severity of their most bothersome vulvovaginal symptom, underwent assessment of vaginal pH and epithelial cytology, and completed other self-report measures including the Female Sexual Function Index (FSFI), Female Sexual Distress Scale (FSDS), and Patient Health Questionnaire-8 for depression (PHQ-8).

main outcome measureThe main outcome measures were the unadjusted correlations and multivariable-adjusted associations with 4 DIVA domain scales designed to assess symptom impact on day-to-day activities, sexual functioning, emotional well-being, and body image/self-concept on a scale of 0 to 4.

resultsAmong 301 women, we detected moderately strong correlations between the DIVA emotional well-being scale and PHQ-8 scores (Pearson correlation coefficient [r] = 0.39) and strong correlations between the DIVA sexual functioning scale and FSFI and FSDS scores (r > 0.50). No significant correlations were detected between any DIVA scales and vaginal pH or epithelial cytology. In adjusted linear-regression analyses, greater vulvovaginal symptom severity was associated with worse DIVA scores for emotional well-being, sexual functioning, and self-concept/body image (average 0.3- to 0.5-point higher DIVA score for each 1-point difference in vulvovaginal symptom severity). Depression symptoms were associated with worse DIVA scores for activities of daily living and emotional well-being (0.2- to 0.4-point higher DIVA score for each 5- point worsening of PHQ-8 score). Women reporting recent sexual activity had lower symptom impact on sexual functioning and self-concept/body image domains (-0.3- to -0.4-point lower DIVA score with weekly sexual activity). CLINICAL IMPLICATIONS: Findings suggest that the impact of postmenopausal vaginal symptoms on functioning and well-being is greater in women with co-morbid depression symptoms and less frequent sexual activity, independent of symptom severity. STRENGTHS & LIMITATIONS: Strengths include the multicenter sample and wide array of measures. Results may not generalize to women with mild symptoms.

conclusionOur results support the construct validity of the DIVA questionnaire for clinical practice and research and indicate that depression and lower frequency of sexual activity are markers of greater impact of postmenopausal vaginal symptoms on multiple dimensions of functioning and quality of life. Hunter MM, Guthrie KA, Larson JC, et al. Convergent-Divergent Validity and Correlates of the Day-to-Day Impact of Vaginal Aging Domain Scales in the MsFLASH Vaginal Health Trial. J Sex Med 2020;17:117-125.

Indexed as

Quality of LifeActivities of Daily LivingAgedAgingBody ImageEmotionsEstradiolEstrogensFemaleHumansMiddle AgedPostmenopauseSelf ConceptSelf ReportSurveys and QuestionnairesSymptom AssessmentEstradiolEstrogensAtrophic VaginitisDyspareuniaPostmenopausal Sexual FunctioningSexual HealthVulvovaginitisWomen’s Health

Identifiers

PMID31812686
PMCPMC6956841
OpenAlexW2991736781

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.